Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.04M Sell
20,000
-74,200
-79% -$26.5M 0.2% 144
2025
Q4
$30.8M Buy
94,200
+81,700
+654% +$25.9M 0.81% 24
2025
Q3
$3.53M Buy
+12,500
New +$3.63M 0.09% 233
2024
Q4
Sell
-40,500
Closed -$13M 448
2024
Q3
$13M Buy
40,500
+10,500
+35% +$3.43M 0.37% 85
2024
Q2
$9.37M Hold
30,000
0.27% 116
2024
Q1
$8.53M Buy
30,000
+12,500
+71% +$3.66M 0.27% 112
2023
Q4
$5.04M Buy
+17,500
New +$4.77M 0.2% 127

Other funds holding AMGN

J. Goldman & Co's AMGN Position: Q1 2026 in Review

J. Goldman & Co reduced its Amgen (AMGN) stake by 77% in Q1 2026, selling an estimated $12M and leaving 9,900 shares worth $3.48M. The position accounts for 0.1% of the portfolio, ranked #236.

J. Goldman & Co first reported a position in AMGN in Q2 2022 and has held it in 10 quarters since. The position peaked at $27.8M in Q3 2023. 3,127 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • J. Goldman & Co held 9,900 shares of Amgen worth $3.48M as of Q1 2026.
  • J. Goldman & Co sold 33,588 Amgen shares in Q1 2026, an estimated $12M.
  • Amgen made up 0.1% of J. Goldman & Co's portfolio in Q1 2026, its #236 holding.
  • J. Goldman & Co first reported a position in Amgen in Q2 2022 and has held it in 10 quarters since.
  • J. Goldman & Co's Amgen position peaked at $27.8M in Q3 2023.
  • 3,127 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.